ChinaPeptides (revision 30)
Old revision·05:33, 5 Mar 2025·TitrationTheo
| ChinaPeptides Co., Ltd. (QYAOBIO)Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | ChinaPeptides Co., Ltd. (QYAOBIO) |
| Trading name | QYB |
| Other designations | QYB Biotech, ChinaPeptides Co., Ltd. (QYAOBIO) |
| Identity | |
| Founded | 2008 |
| Headquarters | Shanghai, China |
| Industry | Research-compound supply |
| Shop domain | Visit QYB |
| Products and documentation | |
| Product scope | custom-synthesis peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| Organisation infobox · conventions | |
ChinaPeptides Co., Ltd. (QYAOBIO) (trading as QYB; qyaobiopeptides.com) is a peptide supplier trading as QYB from Shanghai, China, incorporated in 2008, whose catalogue centres on custom synthesis alongside a range of stock research peptides.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in 2008, the organisation has a mid-length operating history among the entities covered here.[1] It trades under two names — a company name and the designation QYAOBIO — which appear together in its own material and separately in purchaser reports, a duplication that has caused enough confusion for editors to record both in the article's opening sentence.[2]
The distinguishing feature of the catalogue is its emphasis on custom synthesis: sequences made to a purchaser's specification rather than drawn from stock. That is a materially different business from stock distribution, and this article treats it as such.
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Purchaser reports on custom orders describe a quotation stage, a stated lead time, and delivery with a certificate that in this set has usually included a mass-confirmation result alongside the purity figure.[5] Mass confirmation by mass spectrometry addresses a question that a purity figure does not — whether the material is the intended sequence at all — and its presence on a custom-synthesis certificate is the minimum a purchaser should expect.[6]
Stock-item reports describe conventional practice with purity-and-appearance certificates. As elsewhere, self-published claims about facilities are not corroborated here.[2]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Custom synthesis | Sequence to specification, scale to order | Certificate with purity and mass confirmation |
| Stock research peptides | Incretin analogues, repair peptides | Certificate, purity |
| SARMs | Bulk | Certificate, purity |
| Raw materials and oils | Bulk | Certificate, limited detail |
A custom-synthesis house and a stock distributor differ in the risks a purchaser carries. Custom work introduces the possibility of a synthesis that is technically successful but not the sequence intended; stock distribution introduces the possibility of a mislabelled vial. Neither risk is hypothetical and the mitigations differ.[6]
See also
References
- ^ a b National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b c Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ a b United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.